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Abstract
Objective To determine the possible additive effect of
midazolam, a GABAA agonist, on the end-tidal
concentration of isoflurane that prevents movement
(MACNM) in response to noxious stimulation.
Study design Randomized cross-over experimental
study.
Animals Six healthy, adult intact male, mixed-breed
dogs.
Methods After baseline isoflurane MACNM (MACNM-
B) determination, midazolam was administered as a
low (LDS), medium (MDS) or high (HDS) dose series
of midazolam. Each series consisted of two dose
levels, low and high. The LDS was a loading dose
(Ld) of 0.2 mg kg)1 and constant rate infusion (CRI)
(2.5 lg kg)1 minute)1) (LDL), followed by an Ld
(0.4 mg kg)1) and CRI (5 lg kg)1 minute)1) (LDH).
The MDS was an Ld (0.8 mg kg)1) and CRI
(10 lg kg)1 minute)1) (MDL) followed by an Ld
(1.6 mg kg)1) and CRI (20 lg kg)1 minute)1)
(MDH). The HDS was an Ld (3.2 mg kg)1) and
CRI (40 lg kg)1 minute)1) (HDL) followed by an Ld
(6.4 mg kg)1) and CRI (80 lg kg)1 minute)1)
(HDH). MACNM was re-determined after each dose
in each series (MACNM-T).
Results The median MACNM-B was 1.42. MACNM-B
did not differ among groups (p > 0.05). Percentage
reduction in MACNM was significantly less in the
LDS (11 ± 5%) compared with MDS (30 ± 5%) and
HDS (32 ± 5%). There was a weak correlation
between the plasma midazolam concentration and
percentage MACNM reduction (r = 0.36).
Conclusion and clinical relevance Midazolam doses
in the range of 10–80 lg kg)1 minute)1 signifi-
cantly reduced the isoflurane MACNM. However,
doses greater than 10 lg kg)1 minute)1 did not
further decrease MACNM indicating a ceiling effect.
Keywords anaesthesia, dog, isoflurane, midazolam,
minimum alveolar concentration reduction.
Introduction
The potency of inhalational anesthetics is usually
evaluated using the concept of the minimum alve-
olar concentration (MAC), which is the alveolar
concentration at which 50% of patients do not re-
spond with purposeful movement to a supramaxi-
mal noxious stimulus (Merkel & Eger 1963).
Because reflexive, nonpurposeful movement is per-
missible during MAC determination, the potential
for confusion in interpretation of purposeful versus
nonpurposeful movement exists, and this makes the
process somewhat subjective. From a clinical
standpoint, determining the lowest alveolar con-
centration of an anesthetic that abolishes all
movement, i.e., MAC-no movement (MACNM), in
response to a noxious stimulus is more relevant. It is
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generally accepted that an end-tidal concentration
30–50% greater than the MAC is necessary to
abolish all movement in response to noxious stim-
ulation (Eger et al. 1965; Quasha et al. 1980).
Isoflurane causes dose-dependent cardiovascular
and respiratory depression; therefore, sedatives and
analgesics are often administered concurrently to
reduce the dose of isoflurane and, thereby, decrease
cardiopulmonary depression (Muir et al. 2003;
Solano et al. 2006). Midazolam, a water-soluble
benzodiazepine with minimal cardiovascular effects,
is occasionally used for sedation and pre-anesthetic
medication in dogs (Pieri 1983; Greene et al.
1993). 1¢-hydroxymidazolam, the major metabolite
of midazolam, is less potent, and other metabolites
have insignificant pharmacological effects (Pieri
1983; Stoelting & Hillier 2006a). Although there
are no reports on the effects of midazolam on
isoflurane MAC or MAC derivatives in dogs,
midazolam caused a dose-dependent decrease in
halothane MAC in humans (Inagaki et al. 1993)
and enflurane MAC in dogs (Hall et al. 1988a).
The MAC reducing effects of midazolam may be
due to its centrally mediated sedative effects or its
spinally mediated antinociception or the combina-
tion (Yanez et al. 1990; Sumida et al. 1995;
Nishiyama 2006). The antinociceptive activity of
isoflurane (Wakai et al. 2005) and midazolam
(Schofield et al. 1987; Sumida et al. 1995; Kohno
et al. 2006) is mediated via spinal GABAA recep-
tors, thus, it is expected that midazolam would
reduce the amount of isoflurane necessary to
prevent motor movements in response to noxious
stimulation. In the present study, MACNM was used
to evaluate the interaction between midazolam and
isoflurane.
The aim of this study was to determine the effect
of midazolam on MACNM in isoflurane-anesthetized
dogs. It was hypothesized that midazolam would




Six healthy, adult (2–3 years of age) intact female,
mixed-breed dogs (19.1 ± 2.2 kg) provided by a
commercial vendor were used in the study. Food
was withheld for 12 hours prior to anesthesia,
but access to water was allowed. The study was
approved by the University of Tennessee Institu-
tional Animal Care and Use Committee (Protocol
No. 1633).
Experimental design
Each dog was studied on three occasions using a
randomized crossover design, with a minimum of
7 days between experiments. A 6 · 3 table was
created with the six rows representing dogs and the
three columns representing weeks 1–3. Each treat-
ment was applied to two dogs so that all treatments
were represented each week and each dog received
all treatments over the 3-week period. After the
table was devised, dogs were randomly assigned,
one to each row in the table.
Anesthesia
Anesthesia was induced with isoflurane in oxygen
delivered via a mask from a circle system. After
tracheal intubation, anesthesia was maintained
with isoflurane in oxygen (2 L minute)1) using a
small animal anesthetic machine (North American
Drager, Telford, PA, USA). Dogs were positioned in
left lateral recumbency. Ventilation was controlled
to maintain the end-tidal carbon dioxide partial
pressure (PE¢CO2) between 35 and 45 mmHg (4.7–
6 kPa). End-tidal isoflurane (E¢ISO) and PE¢CO2 val-
ues were monitored with an infrared gas analyzer
(Criticare Systems, Waukesha, WI, USA). Samples
were drawn from the proximal end of the endotra-
cheal tube at a rate of 150 mL minute)1. The gas
analyzer was calibrated at the start of each experi-
ment with the calibration gases supplied by the
manufacturer (1% isoflurane in 5% CO2 and 60%
N2O; Criticare Systems). An 18-gauge (6.3 cm)
catheter (Milacath; Mila International, Erlanger,
KY, USA) was placed in the right jugular vein to
facilitate collection of blood for determination of
midazolam and 1¢-hydroxymidazolam plasma con-
centrations, and a second 18-gauge (5 cm) catheter
(Milacath; Mila International) was placed in a ce-
phalic vein for infusion of acetated Ringer’s solution
(3 mL kg)1 hour)1) (Abbott Laboratories, North
Chicago, IL, USA) and midazolam. Body tempera-
ture was monitored using an esophageal probe
(Criticare Systems), and a circulating warm-water
blanket and warm air blanket (Bair Hugger; Arizant
Inc., MN, USA) were used to maintain body tem-
perature within the normal range (37.5–38.5 C).
Heart rate and ECG were monitored continuously.
Arterial blood pressure was monitored continuously
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from a 22-gauge (2.5 cm) catheter (Milacath, Mila
International) in a dorsal pedal artery, using a new
disposable transducer (Baxter Healthcare Corpora-
tion, Irvine, CA, USA) and monitor (Criticare
Systems). The mid-sternum was taken as the zero
point when dogs were in lateral recumbency. All
catheters were placed aseptically and no anti-
biotic was administered. Approximately 45 minutes
after induction of anesthesia, and with the E¢ISO
held constant at 2.0% for at least 20 minutes,
determination of baseline MACNM (MACNM-B) was
initiated.
MACNM-B determination
A noxious stimulus (50 V, 50 Hz for 10 ms) was
delivered (Grass Instrument Company, Quincy, MA,
USA) via two 25-gauge electrode needles inserted
subcutaneously 5 cm apart over the mid-ulnar
area. Two single stimuli, with a 5-second interval,
were delivered initially, followed 5 seconds later by
a continuous stimulus of 5 seconds’ duration,
which was repeated after 5 seconds (Valverde et al.
2003). Withdrawal of a limb or any movement of
the head or chewing movements after stimulation
was deemed to be a positive response. Twitching of
the stimulated limb was not regarded as a positive
response. The E¢ISO was then increased or decreased
by 0.1 vols% depending on whether the response
was positive or negative, respectively, and the
noxious stimulus was re-applied following a 20-
minute equilibration period. The lowest E¢ISO that
abolished all movements in response to the stimulus
was considered the MACNM-B. The MACNM-B was
determined in duplicate, and the mean value was
taken as MACNM-B for that dog on that treatment
day. However, if the difference between the two
MACNM-B values was greater than 10%, a third
MACNM-B was performed and averaged with the first
two to attain MACNM-B.
Drug administration
After MACNM-B determination, dogs were treated
with either a low (LDS), medium (MDS), or high
dose series (HDS) of midazolam HCL 0.5% (Hospira,
Inc., Lake Forest, Illinois, USA). Each dose series
(Table 1) consisted of two loading doses (Ld) and
two corresponding constant rate infusions.
Midazolam was administered as follows:
• LDS: An Ld of 0.2 mg kg)1 and a constant rate
infusion (CRI) of 2.5 lg kg)1 minute)1 (LDL) fol-
lowed by an Ld of 0.4 mg kg)1 and a CRI of
5 lg kg)1 minute)1 (LDH).
• MDS: An Ld of 0.8 mg kg)1 and a CRI of
10 lg kg)1 minute)1 (MDL) followed by an Ld of
1.6 mg kg)1 and a CRI of 20 lg kg)1 minute)1
(MDH).
Table 1 Effect of IV midazolam on isoflurane MACNM in dogs (n = 6)
Midazolam CRI












LDL 2.5 1.40 ± 0.07a 127 ± 29b 1.24 ± 0.04c 146 ± 18e )11 ± 5f 129 ± 242h ND
LDH 5 NA – 1.21 ± 0.04c 136 ± 17e )12 ± 5f 211 ± 237h 114 ± 155k
Medium dose series
MDL 10 1.47 ± 0.08a 85 ± 28b 1.01 ± 0.04d 134 ± 14e )30 ± 5g 372 ± 235h 94 ± 149k
MDH 20 NA – 1.00 ± 0.04d 117 ± 14e )30 ± 5g 788 ± 237hi 158 ± 150k
High dose series
HDL 40 1.36 ± 0.08a 163 ± 28b 1.00 ± 0.04d 128 ± 14e )27 ± 5g 1490 ± 234i 620 ± 147k
HDH 80 NA – 0.94 ± 0.04d 105 ± 16e )32 ± 5g 3583 ± 243j 2424 ± 158l
CRI, continuous rate infusion; MAC, minimum alveolar concentration; H-midazolam, 1¢-hydroxymidazolam; ND, not detectable (less
than 7.5 ng mL)1); Time-to-MACNM-B, time to determine MACNM-B in minutes from induction to completion of MACNM-B in duplicate;
Time-to-MACNM-T, time to determine MACNM-T in minutes from start of CRI to completion of MACNM-T in duplicate; % Change,
calculated from MACNM-B = [(MACNM-T ) MACNM-B)/ MACNM-B] · 100; NA, not applicable- MACNM-B was only determined for the initial
dose in each series; LDL, LDH: Low and high doses, respectively, in low dose series; MDL, MDH: Low and high doses, respectively, in
medium dose series; HDL, HDH: Low and high doses, respectively, in high dose series.
*The MACNM data are expressed as raw mean ± SEM. Time-to-MACNM and plasma concentrations of midazolam and 1¢-
hydroxymidazolam data are expressed as least square means ± SE of the means. Values with different letters in each column are
significantly different (p < 0.05).
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• HDS: An Ld of 3.2 mg kg)1 and a CRI of
40 lg kg)1 minute)1 (HDL) followed by an Ld of
6.4 mg kg)1 and a CRI of 80 lg kg)1 minute)1
(HDH).
The loading and infusion doses were made up to
equal volumes for all the dogs (1.5 mL kg)1 for Ld
and 3 mL kg)1 hour)1 for the CRI) using normal
saline, administered with a syringe pump (Medfu-
sion 2010i; Medox Inc, Duluth, GA, USA) and
delivered through the cephalic vein catheter. Each
loading dose was given over 20 minutes, and the
CRI was started simultaneously (Hall et al. 1988a).
Determination of the first treatment MACNM
(MACNM-T) in each dose series was initiated 60 min-
utes after beginning the CRI and with the E¢ISO held
constant for at least 20 minutes at the MACNM-B
value. The second Ld and CRI were administered,
without a washout period, immediately after deter-
mination of the MACNM-T for the first dose in the
series. The MACNM-T determination for the second
dose in the series was initiated 60 minutes after the
start of the second infusion.
The MACNM-T was determined as described for
MACNM-B. A blood sample (3 mL) was collected
from the right jugular vein into a lithium heparin
tube immediately after the last MACNM-T determi-
nation, and the plasma was harvested and stored at
)80 C prior to determination of plasma midazolam
and 1¢-hydroxymidazolam concentrations.
Drug analysis
Analysis of midazolam and 1¢-hydroxymidazolam in
plasma samples was conducted using reversed phase
HPLC. The system consisted of a 2695 separations
module and a 2487 UV detector (Waters, Milford,
MA, USA). Separation was attained on a Waters
Symmetry C18 3.9 · 150 mm (5 lm) protected by a
5 lm Symmetry guard column. The mobile phase
was an isocratic mixture of 0.01 M sodium acetate pH
4.7 with concentrated glacial acetic acid and aceto-
nitrile (69:31). It was prepared fresh daily using
double-distilled, deionized water filtered (0.22 lm)
and degassed before use. The flow rate was
1.0 mL minute)1, and UV absorbance was measured
at 220 nm. The column was at ambient temperature.
Frozen samples were thawed and vortexed. One
milliliter of plasma sample was placed in 15 mL
screw cap tubes and mixed with 1 mL of H2O,
250 lL of 7.5 M NaOH, and 5 mL of methylene
chloride. The tubes were rocked for 30 minutes and
then centrifuged for 20 minutes at 1302 g. The
organic layer (bottom layer) was removed and
placed into a clean glass tube and evaporated with
nitrogen gas. The residue was reconstituted in
150 lL of the mobile phase and placed in HPLC
vials; a 100 lL volume was then injected into the
HPLC system.
Standard curves for plasma analysis were pre-
pared by spiking dog plasma with midazolam and
1¢-hydroxymidazolam, which produced a linear
concentration range of 10–2500 ng mL)1. Spiked
standards were treated exactly as plasma samples
for drug determination. Recovery averaged 94% for
both drugs. Intra-assay variability ranged from
0.6% to 5.0% for midazolam and 0.8% to 5.7% for
1¢-hydroxymidazolam, while inter-assay variability
ranged from 1.8% to 8.6% for midazolam and 3.8%
to 7.6% for 1¢-hydroxymidazolam.
Statistical analysis
A commercial software program, SAS, version 9.1.3
(SAS Institute, Cary, NC, USA), was used for all
analyses. Percentage change in MACNM was calcu-
lated as [(MACNM-T ) MACNM-B)/MACNM-B] · 100.
A mixed model ANOVA was used to determine the
effect of treatment on percentage change in MACNM.
Independent variables included in the model were
treatment, body weight, time-to-MACNM-T and
week. Dog was included as a random effect in the
model. A test for differences in MACNM-B among
treatment groups was performed using the same
model, but substituting time-to-MACNM-B in place
of MACNM-T. The model to determine the effect of
treatment on midazolam and 1¢-hydroxymidazolam
plasma concentration included group, time-to-
MACNM-T and body mass as independent variables.
Dog and dog-group interaction were included as
random factors in the model. The distributions of
residuals from the models were used to evaluate
model fit to the data. The assumption that the
residuals were normally distributed was evaluated
with the W statistic of Shapiro–Wilk. When possi-
ble, data were transformed to meet this assumption.
Differences in time-to-extubation after cessation
of isoflurane and midazolam delivery among
treatment groups were evaluated using paired t
tests. Correlation between plasma concentrations of
midazolam and 1¢-hydroxymidazolam was deter-
mined using the method of Pearson. The MAC data
are expressed as raw mean ± standard error of the
mean (SEM). Time-to-MACNM and plasma concen-
trations of midazolam and 1¢-hydroxymidazolam
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data are expressed as least square means
(LSM) ± SEM. A two-tailed p-value of <0.05 is
considered significant for all tests.
Results
The median MACNM-B was 1.42 with interquar-
tile ranges of 1.2–1.6%. There was no significant
effect of dog, week or body weight on MACNM-B or
MACNM-T. MACNM-B was not different among groups
(p > 0.05). The times to determine MACNM-B and
MACNM-T did not differ among treatments (p > 0.05).
MACNM-T did not differ significantly between the low
and high doses in any dose series. MACNM-T in LDS
was significantly different from MDS and HDS; how-
ever, MACNM-T was not different between the latter
groups (p > 0.05). Percentage decrease in MACNM
ranged from 11 ± 5 in LDL to 32 ± 5 in HDH
(Table 1). Percentage change in MACNM was signi-
ficantly lower in LDS compared to MDS and HDS;
however, it did not differ between MDS and HDS.
Plasma midazolam concentrations were not sig-
nificantly different between the LDL and LDH, or
between MDL and MDH. However, concentrations
were significantly greater in HDH compared to HDL
(Table 1). Plasma midazolam concentrations did not
differ between the LDS and MDS but were signifi-
cantly greater in HDS. Plasma concentrations of
1¢-hydroxymidazolam were less than the detectable
limit of the HPLC technique (7.5 ng mL)1) in four of
six dogs in the LDL group; therefore, the results for
this group were not analyzed. Plasma 1¢-hydrox-
ymidazolam concentrations were significantly
greater in the HDH group (Table 1). There was a
weak (r = 0.36) but significant (p = 0.03) correla-
tion between plasma midazolam concentrations and
percentage change in MACNM (Fig. 1). The correla-
tion between plasma 1¢-hydroxymidazolam concen-
tration and percentage MACNM reduction was weak
(r = 0.32) and not significant (p = 0.07). The
median value for overall extubation time was
5 minutes (range 3–13 minutes). The time-to-extu-
bation was 7.8 ± 1.4, 7.1 ± 1.3 and 5.1 ± 1.3
minutes, for LDS, MDS and HDS, respectively, and
did not differ (p > 0.05) among groups.
Discussion
The results of this study indicate that midazolam, a
GABAA agonist, dose-dependently decreases isoflu-
rane MACNM in dogs; however, there appears to be a
ceiling to this effect as the maximum reduction in
MACNM occurred at the lower dose of the MDS.
Percentage decrease in MACNM in LDS (11 ± 5)
was not considered to be clinically significant. The
midazolam doses used in the MDS and HDS are
greater than doses used clinically (Greene et al.
1993), and were based on doses used in enflurane
MAC studies in dogs (Hall et al. 1988a,b). The
range of midazolam doses was chosen to determine
if dose–response and ceiling effects exist in regard to
isoflurane MACNM reduction, as has been reported
for midazolam and enflurane MAC in dogs (Hall
et al. 1988a,b). Although midazolam has a rela-
tively short context-sensitive half-time compared
with other benzodiazepines, its mean elimination
half-life is 77 ± 18 minutes after IV administration
to dogs (Court & Greenblatt 1992); thus, it was
unrealistic to have a washout period between the
infusions in each dose series. In the absence of a
washout, the first drug infusion could have influ-
enced plasma concentrations during the second
infusion in each dose series, resulting in greater
than expected plasma concentrations of midazolam
during the second infusion in the series. Therefore,
it is more meaningful to interpret the effect of
Figure 1 Diagram depicts the corre-
lation between plasma midazolam
concentrations and percentage
change in MACNM. There was a weak
but significant (p = 0.03) correlation
between plasma midazolam concen-
trations and percentage change in
MACNM.
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midazolam on MACNM based on the plasma drug
concentrations.
Traditionally, MAC is used as a measure of the
potency of inhalational anesthetics and it is now
understood that MAC evaluates the effect of inha-
lational anesthetics on spinal cord neurons, and is
independent of cerebral function (King & Rampil
1994; Yao et al. 2008). Derivatives of MAC, such
as the MAC that blocks autonomic responses
(MACBAR), have also been described (Docquier et al.
2003). In the present study, another MAC deriva-
tive, MACNM, defined as the minimum end-tidal
concentration of anesthetic preventing motor move-
ment in response to noxious stimulation, was used
to evaluate the interaction between isoflurane and
midazolam. It is the authors’ impression that
MACNM reduces the subjectivity inherent in tradi-
tional MAC studies and is more clinically relevant.
The median MACNM-B value (1.42%) in the present
study is approximately 16% greater than the
traditional isoflurane MAC values reported from
the authors’ laboratory (1.22 ± 0.22) (Wilson et al.
2008a). In contrast, a comparable endpoint to
MACNM in halothane anesthetized ponies was
approximately 60% greater than MAC (Doherty
et al. 1997). The greater value for MACNM relative
to MAC in the pony study may be due to a number
of factors including differences in species, study
methodology, and inhalational anesthetic. The
relationship between MAC and its derivatives varies
with the inhalational anesthetic. For example, the
MACBAR for desflurane and isoflurane in human
patients is approximately 1.3 MAC (Daniel et al.
1998), whereas a MACBAR of 3.5 MAC has been
reported for sevoflurane (Ura et al. 1999). Addi-
tionally, the MACAWAKE is 0.34 MAC for isoflurane
and sevoflurane (Eger 2001); yet, a value of 0.59
MAC is reported for halothane (Gaumann et al.
1992).
The maximum isoflurane MACNM reduction in
the present study was approximately 30% at a
mean plasma midazolam concentration of
372 ng mL)1. Although MACNM-T was significantly
decreased in the LDS, this decrease was not consid-
ered to be clinically significant, as the MAC can vary
up to 10–15% among individuals (Stoelting &
Hillier 2006b). A number of studies have investi-
gated the MAC-sparing effect of midazolam in
humans and dogs, and it appears that the magni-
tude of MAC reduction is highly variable. In human
subjects, a plasma midazolam concentration of
539 ng mL)1 reduced halothane MAC by up to
70% (Inagaki et al. 1993). In dogs, midazolam
concentrations of approximately 950 ng mL)1 and
1500 ng mL)1 reduced enflurane MAC by 55%
(Hall et al. 1988b) and 60% (Hall et al. 1988a),
respectively. The differences in study results could
be due to different MAC endpoints, the interaction
between midazolam and the different inhalational
agents, and variability in midazolam pharmacody-
namics among species. It is possible that differences
exist in the density and distribution of GABAA
receptors and its subtypes in different species, which
may explain interspecies variability in the clinical
effects of benzodiazepines. There may also be differ-
ences in the mechanisms of spinal cord inhibition
among volatile anesthetics. The effect of isoflurane
and enflurane on reduction of spontaneous action
potential firing in rat spinal cord ventral horn
preparations was mediated by GABAA and glycine
receptors; however, the fraction of inhibition med-
iated by the two receptor systems differed between
the two volatile anesthetics (Grasshoff & Antkowiak
2006). Differences in the interaction of inhalational
and injectable anesthetics have also been demon-
strated; and, in dogs, comparable plasma concen-
trations of ketamine decreased sevoflurane MAC by
40% (Wilson et al. 2008b) and isoflurane MAC
by 27–44% (Solano et al. 2006).
In common with other MAC studies (Hall et al.
1988a), this study demonstrated a ceiling to
midazolam’s effect on MACNM, and there was a
weak correlation between plasma midazolam and
1¢-hydroxymidazolam concentrations and percent-
age MACNM reduction. The ceiling effect is thought
to be due to saturation of GABAA receptors after
administration of higher doses of midazolam (Hall
et al. 1988a; Inagaki et al. 1993). Saturation of
GABAA receptors may occur at lower plasma
concentrations of midazolam when isoflurane is
being administered concurrently, as both agents
bind GABAA receptors. Thirty-six percent of the
reduction in spontaneous action potential firing
observed after isoflurane exposure in an in vitro
ventral horn preparation was mediated by GABAA
receptors (Grasshoff & Antkowiak 2006); thus, the
ceiling effect of midazolam on isoflurane MACNM
could be due to a lack of availability of GABAA
receptors in the dorsal horn.
Mean plasma midazolam concentrations of
372 ng mL)1 decreased MACNM by approximately
30%; however, an almost 10-fold increase in plasma
concentrations up to 3583 ng mL)1 (HDS treat-
ment) did not further significantly decrease MACNM.
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In comparison, previous studies in dogs have shown
that the ceiling effect on enflurane MAC reduction
occurred between 950 and 1500 ng mL)1 (Hall
et al. 1988a,b), which is considerably greater than
in the present study. This disparity between plasma
midazolam concentrations and the onset of a ceiling
effect among studies is possibly due to differences in
interaction of midazolam with the different inhala-
tional anesthetics (Grasshoff & Antkowiak 2006).
Differences in midazolam detection assay could also
be considered as another source of variability among
different studies.
The decrease in MACNM by midazolam may be
due to its analgesic and/or sedative effects. How-
ever, determining the mechanism for the reduction
in MACNM was beyond the scope of this study.
Although it is generally accepted that systemically
administered midazolam has minimal antinocicep-
tive effects in dogs, midazolam reduced Ad fiber-
evoked responses in dorsal horn neurons and C
fiber-mediated activity in a model of neuropathic
pain in rats (Kontinen & Dickenson 2000). In mice,
systemic midazolam demonstrated antinociceptive
effects in an inflammatory pain model, but not in a
thermal model (Nishiyama 2006). Intrathecal
administration of midazolam produced dose-depen-
dent antinociception to thermally evoked pain in
rats (Yanez et al. 1990), and intravenous midazo-
lam suppressed noxiously evoked activity of spinal
wide dynamic range neurons in cats (Sumida et al.
1995). Therefore, it is plausible that spinally med-
iated analgesia may play a role in the isoflurane
MACNM sparing effects of midazolam.
In conclusion, midazolam caused a clinically
important and statistically significant decrease in
the MACNM of isoflurane in dogs when infused at
10 lg kg)1 minute)1. Doses greater than 10 lg
kg)1 minute)1 did not cause any further decrease
in MACNM, indicating a ceiling on the MACNM
sparing effect of midazolam.
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